|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dumache R, Rogobete AF, Andreescu N and
Puiu M: Genetic and epigenetic biomarkers of molecular alterations
in oral carcinogenesis. Clin Lab. 61:1373–1381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Manrique OJ, Leland HA, Langevin CJ, Wong
A, Carey JN, Ciudad P, Chen HC and Patel KM: Optimizing outcomes
following total and subtotal tongue reconstruction: A systematic
review of the contemporary literature. J Reconstr Microsurg.
33:103–111. 2017. View Article : Google Scholar
|
|
4
|
Bernier J, Domenge C, Ozsahin M,
Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P,
Rolland F, Bolla M, et al: European Organization for Research and
Treatment of Cancer Trial 22931: Postoperative irradiation with or
without concomitant chemotherapy for locally advanced head and neck
cancer. N Engl J Med. 350:1945–1952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cooper JS, Pajak TF, Forastiere AA, Jacobs
J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et
al: Radiation Therapy Oncology Group 9501/Intergroup: Postoperative
concurrent radiotherapy and chemotherapy for high-risk
squamous-cell carcinoma of the head and neck. N Engl J Med.
350:1937–1944. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Winquist E, Oliver T and Gilbert R:
Postoperative chemoradiotherapy for advanced squamous cell
carcinoma of the head and neck: A systematic review with
meta-analysis. Head Neck. 29:38–46. 2007. View Article : Google Scholar
|
|
7
|
Chinn SB and Myers JN: Oral cavity
carcinoma: Current management, controversies, and future
directions. J Clin Oncol. 33:3269–3276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daigo Y and Nakamura Y: From cancer
genomics to thoracic oncology: Discovery of new biomarkers and
therapeutic targets for lung and esophageal carcinoma. Gen Thorac
Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Daigo Y, Takano A, Teramoto K, Chung S and
Nakamura Y: A systematic approach to the development of novel
therapeutics for lung cancer using genomic analyses. Clin Pharmacol
Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, et
al: Increases of amphiregulin and transforming growth factor-alpha
in serum as predictors of poor response to gefitinib among patients
with advanced non-small cell lung cancers. Cancer Res.
65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishikawa N, Daigo Y, Yasui W, Inai K,
Nishimura H, Tsuchiya E, Kohno N and Nakamura Y: ADAM8 as a novel
serological and histochemical marker for lung cancer. Clin Cancer
Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kakiuchi S, Daigo Y, Ishikawa N, Furukawa
C, Tsunoda T, Yano S, Nakagawa K, Tsuruo T, Kohno N, Fukuoka M, et
al: Prediction of sensitivity of advanced non-small cell lung
cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–3043.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kato T, Daigo Y, Hayama S, Ishikawa N,
Yamabuki T, Ito T, Miyamoto M, Kondo S and Nakamura Y: A novel
human tRNA-dihydrouridine synthase involved in pulmonary
carcinogenesis. Cancer Res. 65:5638–5646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki C, Daigo Y, Ishikawa N, Kato T,
Hayama S, Ito T, Tsuchiya E and Nakamura Y: ANLN plays a critical
role in human lung carcinogenesis through the activation of RHOA
and by involvement in the phosphoinositide 3-kinase/AKT pathway.
Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kakiuchi S, Daigo Y, Tsunoda T, Yano S,
Sone S and Nakamura Y: Genome-wide analysis of organ-preferential
metastasis of human small cell lung cancer in mice. Mol Cancer Res.
1:485–499. 2003.PubMed/NCBI
|
|
17
|
Taniwaki M, Daigo Y, Ishikawa N, Takano A,
Tsunoda T, Yasui W, Inai K, Kohno N and Nakamura Y: Gene expression
profiles of small-cell lung cancers: Molecular signatures of lung
cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
18
|
Oshita H, Nishino R, Takano A, Fujitomo T,
Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, et
al: RASEF is a novel diagnostic biomarker and a therapeutic target
for lung cancer. Mol Cancer Res. 11:937–951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayama S, Daigo Y, Yamabuki T, Hirata D,
Kato T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Phosphorylation and activation of cell division cycle associated 8
by aurora kinase B plays a significant role in human lung
carcinogenesis. Cancer Res. 67:4113–4122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Tanaka S, Yasui W, Takeshima Y, Inai K, Nishimura H, et al:
Characterization of SEZ6L2 cell-surface protein as a novel
prognostic marker for lung cancer. Cancer Sci. 97:737–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kato T, Sato N, Hayama S, Yamabuki T, Ito
T, Miyamoto M, Kondo S, Nakamura Y and Daigo Y: Activation of
Holliday junction recognizing protein involved in the chromosomal
stability and immortality of cancer cells. Cancer Res.
67:8544–8553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki C, Takahashi K, Hayama S, Ishikawa
N, Kato T, Ito T, Tsuchiya E, Nakamura Y and Daigo Y:
Identification of Myc-associated protein with JmjC domain as a
novel therapeutic target oncogene for lung cancer. Mol Cancer Ther.
6:542–551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahashi K, Furukawa C, Takano A,
Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, Sone S, et
al: The neuromedin U-growth hormone secretagogue receptor
1b/neurotensin receptor 1 oncogenic signaling pathway as a
therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Taniwaki M, Takano A, Ishikawa N, Yasui W,
Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y and Daigo Y:
Activation of KIF4A as a prognostic biomarker and therapeutic
target for lung cancer. Clin Cancer Res. 13:6624–6631. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamabuki T, Takano A, Hayama S, Ishikawa
N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, et al:
Dikkopf-1 as a novel serologic and prognostic biomarker for lung
and esophageal carcinomas. Cancer Res. 67:2517–2525. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujitomo T, Daigo Y, Matsuda K, Ueda K and
Nakamura Y: Identification of a nuclear protein, LRRC42, involved
in lung carcinogenesis. Int J Oncol. 45:147–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nguyen MH, Koinuma J, Ueda K, Ito T,
Tsuchiya E, Nakamura Y and Daigo Y: Phosphorylation and activation
of cell division cycle associated 5 by mitogen-activated protein
kinase play a crucial role in human lung carcinogenesis. Cancer
Res. 70:5337–5347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hayama S, Daigo Y, Kato T, Ishikawa N,
Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Activation of CDCA1-KNTC2 members of centromere protein complex,
involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kobayashi Y, Takano A, Miyagi Y, Tsuchiya
E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y and Daigo Y:
Cell division cycle-associated protein 1 overexpression is
essential for the malignant potential of colorectal cancers. Int J
Oncol. 44:69–77. 2014. View Article : Google Scholar
|
|
30
|
Thang PM, Takano A, Yoshitake Y, Shinohara
M, Murakami Y and Daigo Y: Cell division cycle associated 1 as a
novel prognostic biomarker and therapeutic target for oral cancer.
Int J Oncol. 49:1385–1393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blangy A, Lane HA, d'Hérin P, Harper M,
Kress M and Nigg EA: Phosphorylation by P34c dc2 regulates spindle
association of human Eg5, a kinesin-related motor essential for
bipolar spindle formation in vivo. Cell. 83:1159–1169. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rapley J, Nicolàs M, Groen A, Regué L,
Bertran MT, Caelles C, Avruch J and Roig J: The NIMA-family kinase
Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for
mitotic spindle formation. J Cell Sci. 121:3912–3921. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferenz NP, Gable A and Wadsworth P:
Mitotic functions of kinesin-5. Semin Cell Dev Biol. 21:255–259.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wakana Y, Villeneuve J, van Galen J,
Cruz-Garcia D, Tagaya M and Malhotra V: Kinesin-5/Eg5 is important
for transport of CARTS from the trans-Golgi network to the cell
surface. J Cell Biol. 202:241–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schneider MA, Christopoulos P, Muley T,
Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller
NS, Theis F, et al: AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five
specific mitosis-associated genes correlate with poor prognosis for
non-small cell lung cancer patients. Int J Oncol. 50:365–372. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Venere M, Horbinski C, Crish JF, Jin X,
Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, et al: The
mitotic kinesin KIF11 is a driver of invasion, proliferation, and
self-renewal in glioblastoma. Sci Transl Med. 7:304ra1432015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kato T, Lee D, Wu L, Patel P, Young AJ,
Wada H, Hu HP, Ujiie H, Kaji M, Kano S, et al: Kinesin family
members KIF11 and KIF23 as potential therapeutic targets in
malignant pleural mesothelioma. Int J Oncol. 49:448–456. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Imai T, Oue N, Nishioka M, Mukai S, Oshima
T, Sakamoto N, Sentani K, Matsusaki K, Yoshida K and Yasui W:
Overexpression of KIF11 in gastric cancer with intestinal mucin
phenotype. Pathobiology. 84:16–24. 2017. View Article : Google Scholar
|
|
39
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wojcik EJ, Buckley RS, Richard J, Liu L,
Huckaba TM and Kim S: Kinesin-5: Cross-bridging mechanism to
targeted clinical therapy. Gene. 531:133–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sarli V and Giannis A: Targeting the
kinesin spindle protein: Basic principles and clinical
implications. Clin Cancer Res. 14:7583–7587. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Martens-de Kemp SR, Nagel R, Stigter-van
Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ and
Brakenhoff RH: Functional genetic screens identify genes essential
for tumor cell survival in head and neck and lung cancer. Clin
Cancer Res. 19:1994–2003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bertran MT, Sdelci S, Regué L, Avruch J,
Caelles C and Roig J: Nek9 is a Plk1-activated kinase that controls
early centrosome separation through Nek6/7 and Eg5. EMBO J.
30:2634–2647. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ma HT, Erdal S, Huang S and Poon RY:
Synergism between inhibitors of Aurora A and KIF11 overcomes
KIF15-dependent drug resistance. Mol Oncol. 8:1404–1418. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nalawansha DA, Gomes ID, Wambua MK and
Pflum MKH: HDAC inhibitor-induced mitotic arrest is mediated by
eg5/kif11 acetylation. Cell Chem Biol. 24:481–492.e5. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Meyen D, Tarbashevich K, Banisch TU,
Wittwer C, Reichman-Fried M, Maugis B, Grimaldi C, Messerschmidt EM
and Raz E: Dynamic filopodia are required for chemokine-dependent
intracellular polarization during guided cell migration in vivo.
eLife. 4:42015. View Article : Google Scholar
|
|
48
|
LoRusso PM, Goncalves PH, Casetta L,
Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons
HM, Ptaszynski M, et al: First-in-human phase 1 study of filanesib
(ARRY-520), a kinesin spindle protein inhibitor, in patients with
advanced solid tumors. Invest New Drugs. 33:440–449. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Good JA, Wang F, Rath O, Kaan HY,
Talapatra SK, Podgórski D, MacKay SP and Kozielski F: Optimized
S-trityl-L-cysteine-based inhibitors of kinesin spindle protein
with potent in vivo antitumor activity in lung cancer xenograft
models. J Med Chem. 56:1878–1893. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Talapatra SK, Anthony NG, Mackay SP and
Kozielski F: Mitotic kinesin Eg5 overcomes inhibition to the phase
I/II clinical candidate SB743921 by an allosteric resistance
mechanism. J Med Chem. 56:6317–6329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S,
Li J, Wu F, Zhang H, Zhao Z, et al: A potent chemotherapeutic
strategy with eg5 inhibitor against gemcitabine resistant bladder
cancer. PLoS One. 10:e01444842015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yin Y, Sun H, Xu J, Xiao F, Wang H, Yang
Y, Ren H, Wu CT, Gao C and Wang L: Kinesin spindle protein
inhibitor SB743921 induces mitotic arrest and apoptosis and
overcomes imatinib resistance of chronic myeloid leukemia cells.
Leuk Lymphoma. 56:1813–1820. 2015. View Article : Google Scholar
|
